01:55 PM EDT, 08/27/2024 (MT Newswires) -- Invivyd ( IVVD ) said Tuesday that its phase 3 Canopy trial showed an 84% reduction in the risk of symptomatic Covid-19 for participants treated with its investigational antibody, pemivibart, compared to placebo over 180 days.

In the B cohort, which consists of a group of all-comer immunocompetent individuals, the rate of symptomatic Covid-19 was 1.9% for those receiving pemivibart compared with 11.9% in a placebo group, the company said.

Invivyd ( IVVD ) shares were down more than 23% in recent trading.

Price: 0.99, Change: -0.30, Percent Change: -23.57